On Friday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was 4.99% up from the session before settling in for the closing price of $4.41. A 52-week range for RXRX has been $3.79 – $12.36.
Annual sales at Healthcare sector company slipped by -35.28% over the past five years. When this article was written, the company’s average yearly earnings per share was at 7.54%. With a float of $414.98 million, this company’s outstanding shares have now reached $485.21 million.
Recursion Pharmaceuticals Inc (RXRX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Recursion Pharmaceuticals Inc stocks. The insider ownership of Recursion Pharmaceuticals Inc is 20.39%, while institutional ownership is 48.73%. The most recent insider transaction that took place on Nov 19 ’25, was worth 166,400. In this transaction Chief Executive Officer of this company sold 40,000 shares at a rate of $4.16, taking the stock ownership to the 913,839 shares. Before that another transaction happened on Nov 19 ’25, when Company’s Officer proposed sale 40,000 for $4.16, making the entire transaction worth $166,400.
Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.53 earnings per share (EPS) during the time that was less than consensus figure (set at -0.42) by -0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.13% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
You can see what Recursion Pharmaceuticals Inc (RXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.60. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 55.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.81, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.23 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) saw its 5-day average volume 19.08 million, a negative change from its year-to-date volume of 29.56 million. As of the previous 9 days, the stock’s Stochastic %D was 92.44%.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 24.33%, which indicates a significant decrease from 71.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.30 in the past 14 days, which was lower than the 0.38 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.16, while its 200-day Moving Average is $5.47. Nevertheless, the first resistance level for the watch stands at $4.72 in the near term. At $4.80, the stock is likely to face the second major resistance level. The third major resistance level sits at $4.96. If the price goes on to break the first support level at $4.47, it is likely to go to the next support level at $4.31. Assuming the price breaks the second support level, the third support level stands at $4.23.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are 520,643K outstanding shares of the company, which has a market capitalization of 2.41 billion. As of now, sales total 58,840 K while income totals -463,660 K. Its latest quarter income was 5,180 K while its last quarter net income were -162,250 K.
